2019 CYIR Finalized

25 MAC-positive while on GBT for at least 6 months and were currently receiving treatment or had stopped treatment <12 months prior to study enrollment. Patients with cystic fibrosis, immunodeficiency syndromes, or amikacin resis- tant isolates (MIC > 64 ug/mL) were excluded. The primary endpoint was culture conversion by month 6. The study included 336 participants (224 ALIS/GBT, 112 GBT), among whom 22% had macrolide-resistant isolates. Significantly more participants who were receiving ALIS achieved the primary endpoint (29%) compared to GBT alone (9%; adjusted OR=4.2, 95% CI=2.1-8.6). The most common adverse events were respiratory related and occurred more frequently in the ALIS arm (87%) compared to GBT-alone (50%), and 17% of ALIS-treated patients had adverse events that resulted in discontinuation of ALIS. Comments 1. This study found that patients treated with ALIS + GBT were more likely to achieve culture-conversion at month 6 compared to GBT-alone. 2. Adverse events were more common in the ALIS+GBT arm, although severe adverse events were similarly distributed between the 2 study arms. 3. There have been no studies comparing ALIS to nebulized (injectable) amikacin. 4. ALIS is the first FDA-approved medication for the treatment of MAC pulmonary disease. 5. Given culture conversion of 30% in the ALIS+GBT arm, novel treatments for MAC lung disease are needed. OTHER ARTICLES OF INTEREST TB Preventive Therapy Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med 2018; 379:454-463. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE, for the BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med 2018; 379:454-463. N Engl J Med 2019; 380:1001-1011. Treatment of TB Disease Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med 2018;379(9):823-33. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Banurekha V, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien J, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Galliez R, Garcia-Prats A, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson K, Johnston J, Jones- Lopez E C, Khan A, Koh W, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Merle CSC, Munang M, Narendran G, Nunn A, Ohkado AA, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, van Soolingen D, Tabarsi P, Trajman A, Trieu L, Viiklepp P, Nguyen VN, Wang J-Y, Yoshiyama T, Menzies D. Comparison of different treatments for isoniazid resis- tant tuberculosis: 2 an individual patient data meta- analysis. Lancet Resp Med 2018; 6:265-75. Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Mendez-Echevarria A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med 2018;15(7):e1002591. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, Ravinetto R, van Loen H, Nair A, Jackson A, Colebunders R, Maartens G, Wilkinson RJ, Lynen L. Prednisone for the prevention of paradoxical tubercu- losis-associated IRIS. N Engl J Med 2018; 379:1915-25. Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, van Deun A, Dat P-T, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID. A trial of a shorter regi- MYCOBACTERIAL INFECTIONS

RkJQdWJsaXNoZXIy MTM1ODMw